Cogent Biosciences Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
258
- Stock Symbol
-
COGT
- Investments
-
1
- Share Price
-
$28.54
- (As of Friday Closing)
Cogent Biosciences General Information
Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Contact Information
Website
www.cogentbio.comCorporate Office
- 275 Wyman Street
- 3rd floor
- Waltham, MA 02451
- United States
Corporate Office
- 275 Wyman Street
- 3rd floor
- Waltham, MA 02451
- United States
Cogent Biosciences Timeline
Cogent Biosciences Stock Performance
As of 13-Nov-2026, Cogent Biosciences’s stock price is $28.54. Its current market cap is $4.97B with 174M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $28.54 | $29.14 | $27.73 - $43.73 | $4.97B | 174M | 2.01M | -$2.26 |
Cogent Biosciences Financials Summary
As of 30-Sep-2026, Cogent Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,072,984 | 5,230,102 | 654,511 | 306,578 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (425,396) | (335,981) | (269,596) | (201,899) |
| Net Income | (407,675) | (328,937) | (255,859) | (192,410) |
| Total Assets | 832,142 | 937,607 | 327,898 | 313,437 |
| Total Debt | 244,220 | 238,797 | 17,467 | 18,853 |
Cogent Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cogent Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cogent Biosciences Comparisons
Industry
Financing
Details
Cogent Biosciences Competitors (73)
One of Cogent Biosciences’s 73 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA |
Cogent Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cogent Biosciences Patents
Cogent Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072922-A1 | Jak2 v617f inhibitors | Pending | 27-Sep-2024 | ||
| AU-2025236956-A1 | Kras inhibitors | Pending | 12-Mar-2024 | ||
| WO-2025193878-A1 | Kras inhibitors | Pending | 12-Mar-2024 | ||
| AU-2024319770-A1 | Compounds for fgfr inhibition | Pending | 07-Aug-2023 | ||
| EP-4757804-A2 | Compounds for fgfr inhibition | Pending | 07-Aug-2023 | C07D471/04 |
Cogent Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cogent Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cogent Biosciences Acquisitions (1)
Cogent Biosciences’s most recent deal was a Merger/Acquisition with Kiq (Biotechnology Company). The deal was made on 06-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kiq (Biotechnology Company) | 06-Jul-2020 | Merger/Acquisition | Biotechnology |
Cogent Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.66 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Cogent Biosciences FAQs
-
When was Cogent Biosciences founded?
Cogent Biosciences was founded in 2014.
-
Where is Cogent Biosciences headquartered?
Cogent Biosciences is headquartered in Waltham, MA.
-
What is the size of Cogent Biosciences?
Cogent Biosciences has 258 total employees.
-
What industry is Cogent Biosciences in?
Cogent Biosciences’s primary industry is Drug Discovery.
-
Is Cogent Biosciences a private or public company?
Cogent Biosciences is a Public company.
-
What is Cogent Biosciences’s stock symbol?
The ticker symbol for Cogent Biosciences is COGT.
-
What is the current stock price of Cogent Biosciences?
As of 13-Nov-2026 the stock price of Cogent Biosciences is $28.54.
-
What is the current market cap of Cogent Biosciences?
The current market capitalization of Cogent Biosciences is $4.97B.
-
Who are Cogent Biosciences’s competitors?
Blueprint Medicines, Senti Biosciences Holdings, Kite Pharma, Apexian Pharmaceuticals, and AnTolRx are some of the 73 competitors of Cogent Biosciences.
-
What is Cogent Biosciences’s annual earnings per share (EPS)?
Cogent Biosciences’s EPS for 12 months was -$2.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
